Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease

Journal of Infection and Chemotherapy

Volumn 11, Issue 1, 2005, Pages 24-31

  Ohashi, Naro ^a   Uematsu, Toshihiko ^b   Nagashima, Satoru ^b   Kanamaru, Mitsutaka ^b   Tajima, Naoyuki ^c   Togawa, Akashi ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shitoro Clinic   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Dialyzability; Hemodialysis; Panipenem betamipron; Predictability

Indexed keywords

BETAMIPRON; PANIPENEM; PANIPENEM PLUS BETAMIPRON;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PATIENT;

EID: 15044350042     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0359-6     Document Type: Article

References (18)

1. Kozawa O, Uematsu T. Pharmacokinetic and dynamic properties of carbapenem antibiotics. Recent Res Dev Antimicrob Agents Chemother 1999;3:441-51.
2. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185-201.
3. Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/ betamipron. Drugs Exp Clin Res 1994;20:241-5.
4. Hirouchi Y, Naganuma H, Kawahara Y, Okada R, Kamiya A, Inui K, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994;66:1-6.
5. Tokunaga J, Kobayashi M, Kitagawa A, Nakamura C, Arimori K, Nakano M. Protective effects of betamipron on renal toxicity during repeated cisplatin administration in rats, and protective mechanism. Renal Failure 1998;20:27-38.
6. Nakashima M, Uematsu T, Kanamaru M, Tajima M, Naganuma H, Hisaoka M, et al. Phase I study of panipenem/betamiprom. I. Single dose study. Chemotherapy 1991;39(S-3):242-64.
7. Nakashima M, Uematsu T, Kanamaru M, Tajima M, Naganuma H, Ichikawa M, et al. Phase I study of panipenem/betamiprom. II. Multiple dose study. Chemotherapy 1991;39(S-3):265-88.
8. Aoki N, Usuda Y, Koda Y, Takasawa T, Wakabayashi N, Hayashi S, et al. Clinical pharmacology and efficacy of panipenem/ betamipron. Chemotherapy 1991;39(S-3):372-84.
9. Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H. Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother 2001;47:51-9.
10. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000;17:1551-7.
11. Craig WA. Pharmacokinetics/pharmacodynamics parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
12. Gulyassy PF, Bottini AT, Stanfel LA, Jarrard EA, Depner TA. Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int 1986;30:391-8.
13. Niwa T, Takeda N, Maeda K, Shibata M, Tatematsu A. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 1988;173:127-8.
14. Spiteller M, Spiteller G, Hoyer G-A. Urofuransaeuren-eine bisher unbekannte Klasse von Stoffwechselprodukten. Chem Ber 1980; 113:699-709.
15. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
16. Sassa T, Matsuno H, Niwa M, Kozawa O, Takeda N, Niwa T, et al. Measurement of furancarboxylic acid, a candidate for uremic toxin in human serum, hair, and sweat, and analysis of pharmacological actions in vitro. Arch Toxicol 2000;73:649-54.
17. Naganuma H, Hirouchi Y, Kawahara Y, Inui K, Tanigawara Y, Yasuhara M, et al. Nephroprotective effect and its mechanism of betamipron. 2. Relationship of renal excretion. Chemotherapy 1991;39(S-3):178-89.
18. Kamiya A, Okumura K, Hori R. Quantitative investigation on renal handling of drugs in rabbits, dogs, and humans. J Pharm Sci 1983;72:440-3.